Titre : Vinblastine

Vinblastine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Electronic Nicotine Delivery Systems

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?

La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués.
Vinblastine Cancer Diagnostic médical
#2

Quels tests précèdent l'administration de vinblastine ?

Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement.
Tests de laboratoire Imagerie médicale Vinblastine

Symptômes 2

#1

Quels sont les effets secondaires courants de la vinblastine ?

Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux.
Effets secondaires Vinblastine Nausées
#2

La vinblastine provoque-t-elle des douleurs ?

Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique.
Douleur Vinblastine Effets indésirables

Prévention 2

#1

La vinblastine a-t-elle un rôle préventif dans le cancer ?

Non, la vinblastine est un traitement et ne prévient pas le développement du cancer.
Prévention du cancer Vinblastine Traitement
#2

Peut-on prévenir les effets secondaires de la vinblastine ?

Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine.
Effets secondaires Vinblastine Médicaments antiémétiques

Traitements 2

#1

Dans quels types de cancer la vinblastine est-elle utilisée ?

Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule.
Lymphome Cancer du poumon Vinblastine
#2

Comment la vinblastine est-elle administrée ?

La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale.
Administration intraveineuse Vinblastine Traitement du cancer

Complications 2

#1

Quelles complications peuvent survenir avec la vinblastine ?

Des complications incluent des infections, des saignements et des problèmes neurologiques.
Complications Vinblastine Infections
#2

La vinblastine peut-elle affecter la moelle osseuse ?

Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs.
Moelle osseuse Vinblastine Dépression médullaire

Facteurs de risque 2

#1

Qui est à risque d'effets indésirables avec la vinblastine ?

Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru.
Facteurs de risque Vinblastine Maladies cardiaques
#2

Les enfants peuvent-ils prendre de la vinblastine ?

Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance.
Vinblastine Pédiatrie Traitement du cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vinblastine : Questions médicales les plus fréquentes", "headline": "Vinblastine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vinblastine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-10", "dateModified": "2025-05-05", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vinblastine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Alcaloïdes de Vinca", "url": "https://questionsmedicales.fr/mesh/D014748", "about": { "@type": "MedicalCondition", "name": "Alcaloïdes de Vinca", "code": { "@type": "MedicalCode", "code": "D014748", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827" } } }, "about": { "@type": "MedicalCondition", "name": "Vinblastine", "alternateName": "Vinblastine", "code": { "@type": "MedicalCode", "code": "D014747", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Christine Chevreau", "url": "https://questionsmedicales.fr/author/Christine%20Chevreau", "affiliation": { "@type": "Organization", "name": "Department of Medicine, Oncopole, Toulouse, France." } }, { "@type": "Person", "name": "Stéphane Culine", "url": "https://questionsmedicales.fr/author/St%C3%A9phane%20Culine", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr." } }, { "@type": "Person", "name": "Gwenaelle Gravis", "url": "https://questionsmedicales.fr/author/Gwenaelle%20Gravis", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France." } }, { "@type": "Person", "name": "Florence Joly", "url": "https://questionsmedicales.fr/author/Florence%20Joly", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology, François Baclesse Cancer Center, Caen, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Electronic Nicotine Delivery Systems and Cardiovascular/Cardiometabolic Health.", "datePublished": "2023-04-27", "url": "https://questionsmedicales.fr/article/37104558", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1161/CIRCRESAHA.123.321565" } }, { "@type": "ScholarlyArticle", "name": "Smoking reduction using an electronic nicotine delivery system (ENDS) with nicotine delivery similar to combustible cigarettes.", "datePublished": "2024-07-29", "url": "https://questionsmedicales.fr/article/39075535", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12954-024-01064-0" } }, { "@type": "ScholarlyArticle", "name": "Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches.", "datePublished": "2023-07-17", "url": "https://questionsmedicales.fr/article/37458789", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00213-023-06401-y" } }, { "@type": "ScholarlyArticle", "name": "Using varenicline in combination with electronic nicotine delivery systems (ENDS).", "datePublished": "2023-08-07", "url": "https://questionsmedicales.fr/article/37611481", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.drugalcdep.2023.110916" } }, { "@type": "ScholarlyArticle", "name": "Electronic nicotine delivery systems (ENDS): A convenient means of smoking?", "datePublished": "2023-08-25", "url": "https://questionsmedicales.fr/article/37634554", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.phrs.2023.106885" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indolizine", "item": "https://questionsmedicales.fr/mesh/D007212" }, { "@type": "ListItem", "position": 6, "name": "Indolizidines", "item": "https://questionsmedicales.fr/mesh/D054836" }, { "@type": "ListItem", "position": 7, "name": "Alcaloïdes indoliques", "item": "https://questionsmedicales.fr/mesh/D026121" }, { "@type": "ListItem", "position": 8, "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "item": "https://questionsmedicales.fr/mesh/D046948" }, { "@type": "ListItem", "position": 9, "name": "Alcaloïdes de Vinca", "item": "https://questionsmedicales.fr/mesh/D014748" }, { "@type": "ListItem", "position": 10, "name": "Vinblastine", "item": "https://questionsmedicales.fr/mesh/D014747" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vinblastine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vinblastine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vinblastine", "description": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?\nQuels tests précèdent l'administration de vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Electronic+Nicotine+Delivery+Systems#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vinblastine", "description": "Quels sont les effets secondaires courants de la vinblastine ?\nLa vinblastine provoque-t-elle des douleurs ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Electronic+Nicotine+Delivery+Systems#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vinblastine", "description": "La vinblastine a-t-elle un rôle préventif dans le cancer ?\nPeut-on prévenir les effets secondaires de la vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Electronic+Nicotine+Delivery+Systems#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vinblastine", "description": "Dans quels types de cancer la vinblastine est-elle utilisée ?\nComment la vinblastine est-elle administrée ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Electronic+Nicotine+Delivery+Systems#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vinblastine", "description": "Quelles complications peuvent survenir avec la vinblastine ?\nLa vinblastine peut-elle affecter la moelle osseuse ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Electronic+Nicotine+Delivery+Systems#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vinblastine", "description": "Qui est à risque d'effets indésirables avec la vinblastine ?\nLes enfants peuvent-ils prendre de la vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Electronic+Nicotine+Delivery+Systems#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués." } }, { "@type": "Question", "name": "Quels tests précèdent l'administration de vinblastine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants de la vinblastine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux." } }, { "@type": "Question", "name": "La vinblastine provoque-t-elle des douleurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique." } }, { "@type": "Question", "name": "La vinblastine a-t-elle un rôle préventif dans le cancer ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, la vinblastine est un traitement et ne prévient pas le développement du cancer." } }, { "@type": "Question", "name": "Peut-on prévenir les effets secondaires de la vinblastine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine." } }, { "@type": "Question", "name": "Dans quels types de cancer la vinblastine est-elle utilisée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule." } }, { "@type": "Question", "name": "Comment la vinblastine est-elle administrée ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la vinblastine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections, des saignements et des problèmes neurologiques." } }, { "@type": "Question", "name": "La vinblastine peut-elle affecter la moelle osseuse ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs." } }, { "@type": "Question", "name": "Qui est à risque d'effets indésirables avec la vinblastine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru." } }, { "@type": "Question", "name": "Les enfants peuvent-ils prendre de la vinblastine ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 05/05/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Eric Bouffet

2 publications dans cette catégorie

Affiliations :
  • Programme in Developmental and Stem Cell Biology, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.

Yaser Hassan Dewir

2 publications dans cette catégorie

Affiliations :
  • Plant Production Department, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia.

Sarah E O'Connor

2 publications dans cette catégorie

Affiliations :
  • Department of Natural Product Biosynthesis, Max Planck Institute for Chemical Ecology, Jena, Germany.

G A Amos Burke

2 publications dans cette catégorie

Affiliations :
  • Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.

Riccardo Finotello

2 publications dans cette catégorie

Affiliations :
  • Department of Small Animal Clinical Sciences, Department of Veterinary Anatomy Physiology and Pathology, Institute of Infection Veterinary and Ecological Sciences, University of Liverpool, Chester High Rd, Neston CH64 7TE, UK.

Yoshihiro Nishida

2 publications dans cette catégorie

Affiliations :
  • Department of Rehabilitation Medicine, Nagoya University Hospital, Nagoya, Japan.
  • Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.

Shunsuke Hamada

2 publications dans cette catégorie

Affiliations :
  • Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.

Tomohisa Sakai

2 publications dans cette catégorie

Affiliations :
  • Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.

Hiroshi Koike

2 publications dans cette catégorie

Affiliations :
  • Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.

Magdalena Markowicz-Piasecka

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland; Department of Applied Pharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland.

Sources (10000 au total)

Smoking reduction using an electronic nicotine delivery system (ENDS) with nicotine delivery similar to combustible cigarettes.

Electronic nicotine delivery systems (ENDS) offer a promising approach to tobacco harm reduction, but many people use both ENDS and combustible cigarettes ("dual use"), which undermines potential risk... Twenty-five cigarette smoking adults, not seeking smoking cessation treatment, but open to using ENDS as a cigarette substitute, were provided with a 12-week supply of BIDI... Over 12 weeks, ENDS use increased to an average of 15.8 occasions per day (SD = 20.2) and self-reported cigarette consumption decreased by 82% from 16.7 cigarettes/day (SD = 6.0) at baseline to 3.0 ci... In this study, the ENDS effectively replicated the subjective rewarding effects of participants' usual brands of cigarettes and led to a substantial reduction in reported cigarettes/day. Exhaled CO sh... ClinicalTrials.gov identifier NCT05855343....

Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches.

Electronic nicotine delivery systems (ENDS) are used by smokers seeking to reduce combustible cigarette (CC) use, but the role of nicotine replacement vs. behavioral and sensory factors is still poorl... To assess the effects on smoking behavior of using nicotine vs. placebo ENDS in smokers using nicotine vs. placebo patches.... Ninety-four daily smokers were enrolled in a study that randomly assigned them to receive ENDS with nicotine vs. without nicotine and skin patches with vs. without nicotine. Smoking reduction and cess... The use of nicotine in ENDS led to significant reductions in smoking (ENDS nicotine vs. placebo difference in CO change = -9.2 ppm; 90% CI (-1.5 ppm, -16.9 ppm)) and was highly correlated with reducti... The presence of nicotine in ENDS was associated with a large reduction in smoking. Additional studies will be needed to determine whether there may be additive effects of nicotine ENDS and nicotine pa...

Using varenicline in combination with electronic nicotine delivery systems (ENDS).

Varenicline is efficacious for smoking cessation, but a return to smokingusually occurs after treatment ends. Electronic nicotine delivery systems (ENDS) may enhance smoking reduction and cessation by... Twenty-five individuals who smoked cigarettes, interested in switching but not seeking cessation treatment, received ENDS for 13 weeks; during weeks 2-13 they received varenicline. Assessments include... Cigarette smoking decreased from 15.6 cigarettes/day (SD=5.6) at baseline to 2.8 cigarettes/day (SD=5.1) at week 13 (paired t(22)=10.24, p<0.0001). 28% of participants were confirmed to be abstinent i... ENDS in combination with varenicline shows promise as a means to reduce dependence on cigarettes and facilitate switching from cigarettes to ENDS....

Young adult responses to taxes on cigarettes and electronic nicotine delivery systems.

Although over half of United States states have passed taxes on electronic nicotine delivery systems (ENDS), recent evidence links ENDS tax rates to increases in smoking, suggesting potentially substa... Observational study of data from the Current Population Survey's 2010-2019 Tobacco Use Supplements.... The United States.... A total of 38 906 18 to 25 year-olds MEASUREMENTS: Multivariable linear regressions estimated two-way fixed effects analyses to assess ENDS and cigarette tax rates' relationships to recent and daily s... A $1 increase in ENDS taxes yielded significant reductions in young adults' daily vaping (... In the United States, higher ENDS tax rates are associated with decreased ENDS use but increased cigarette smoking among 18- to 25-year-olds, with associations reversed for cigarette taxes....

Factors associated with child and adolescent electronic nicotine and non-nicotine delivery systems use: A scoping review.

To identify, characterise and broadly synthesise factors associated with child and adolescent electronic nicotine delivery systems (ENDS) and/or electronic non-nicotine delivery systems (ENNDS) ever-u... Four electronic databases were searched from inception to 3rd June 2022. Non-experimental studies that provided quantitative factors associated with adolescent and/or child ENDS or ENNDS ever-use and/... The search of electronic databases identified 4756 records, 240 of which were included. The majority of studies examined factors categorised within the Biology and Personality domain of the Theory of ... The evidence base on factors associated with ENDS/ENNDS use in children and adolescents is rapidly developing, predominately by research concentrated in high income regions and focused on behavioural-...

The development and validation of an electronic nicotine delivery system (ENDS) image cue stimulus set.

Responsiveness to drug-related cues assesses drug reward in research studies. There are currently no validated visual image cues related to electronic nicotine delivery systems (ENDS), thus, this stud... ENDS users and non-vaping individuals in the United States and Canada were recruited via Amazon MTurk. A total of 120 ENDS-related images and 56 neutral images, matched for visual similarity, were ass... After excluding patterned responses, the data from 926 participants (610 ENDS users, and 316 non-vaping controls) were analyzed. When viewing ENDS-related images, desire-to-vape scores were correlated... Correlational findings of the affective ENDS-related images were similar to those of previous studies validating collections of tobacco and alcohol picture cues, supporting the future use of these sti...

Key Risk Factors Associated With Electronic Nicotine Delivery Systems Use Among Adolescents.

The prevalence of electronic nicotine delivery systems (ENDS) use among US youths has increased significantly during the past decade. Identifying key factors highly associated with ENDS use is essenti... To identify the most important risk factors in wave 4.5 (ie, December 2017 to December 2018) of the Population Assessment of Tobacco and Health Study (PATH) data that are associated with ENDS use in w... This prognostic study examined data from waves 4.5 and 5 of the PATH youth data set using machine learning techniques. The PATH study is a nationally representative longitudinal cohort study of tobacc... Wave 5 current ENDS use status of wave 4.5 adolescents who were tobacco-naive.... The analyzed data set comprised 7943 individuals who were tobacco-naive in wave 4.5. Among this group, 332 participants (4.2%) indicated their present use of ENDS in wave 5, 5047 (63.5%) were aged 12 ... The findings of this study suggest that family and friends play an important role in ENDS use among adolescents. The top-ranking factors associated with ENDS use in this study are areas for further ex...

Combinations of electronic nicotine delivery system device and liquid characteristics among U.S. adults.

The combination of electronic nicotine delivery systems (ENDS) device and liquid characteristics affect user nicotine and toxicant exposure, however population-level national survey studies have not r... U.S. adults (21+) using ENDS at least five days/week (n = 1,179) completed an online survey in 2020 and uploaded photos of their most used device and liquid. Device/liquid combinations were analyzed t... Five device/liquid combinations accounted for 87 % of those reported. The most prevalent combination, reported by 36.2 %, was re-useable devices with adjustable settings and a tank refilled with a fre... Analyzing ENDS device/liquid combinations rather than each separately can allow researchers to better evaluate relationships between use and key outcomes, such as quitting cigarettes and abuse liabili...